Clinical Trial: Intravesical Gemcitabine in Patients With NMIBC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Urinary Bladder Cancer
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Intravesical Gemcitabine in Patients With Nonmuscle Invasive Bladder Cancer With or Without Prior Bacillus Calmette-Guérin Therapy
Brief Summary:
Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer is a well-established treatment for preventing or delaying tumor recurrence after bladder tumor resection.For high-risk non-muscle invasive bladder cancer, immunotherapy in the form of intravesical Bacillus Calmette-Guérin (BCG) can be effective as first-line, nevertheless, the response rate to BCG is suboptimal with many patients failing treatment.Following BCG-failure, however, very few effective therapeutic options exist besides…
Read more